Compare · ISPC vs RVTY
ISPC vs RVTY
Side-by-side comparison of iSpecimen Inc. (ISPC) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- ISPC operates in Health Care, while RVTY operates in Industrials - the two are in different parts of the market.
- RVTY is the larger of the two at $17.66B, about 4598.8x ISPC ($3.8M).
- ISPC has been more active in the news (7 items in the past 4 weeks vs 6 for RVTY).
- RVTY has more recent analyst coverage (24 ratings vs 2 for ISPC).
- Company
- iSpecimen Inc.
- Revvity Inc.
- Price
- -
- -
- Market cap
- $3.8M
- $17.66B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 7
- 6
- Recent ratings
- 2
- 24
Latest ISPC
- iSpecimen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- iSpecimen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Changes in Control of Registrant, Regulation FD Disclosure, Financial Statements and Exhibits
- iSpecimen Expands Into AI-Powered Drug Discovery and Disease Trend Monitoring With Acquisition of Foldlab AI Products
- iSpecimen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form PRE 14A filed by iSpecimen Inc.
- iSpecimen Offers Next-Day Healthy Donor Blood and Launches Development of AI Agent
- SEC Form DEFR14A filed by iSpecimen Inc.
- SEC Form PRER14A filed by iSpecimen Inc.
- SEC Form 8-K filed by iSpecimen Inc.
- iSpecimen Supports Hospital Validation of New Chemistry Analyzer
Latest RVTY
- SEC Form 10-Q filed by Revvity Inc.
- Revvity upgraded by CFRA
- Revvity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Revvity Announces Financial Results for the Third Quarter of 2026
- Revvity Board Declares Quarterly Dividend
- Revvity Launches Signals LabGistics Solution to Connect and Orchestrate Scientific Workflows
- Revvity to Present at Upcoming Investor Conferences
- William Blair initiated coverage on Revvity
- Revvity to Host Investor Day
- VP and CAO Gonzales Anita sold $13,060 worth of shares (84 units at $155.48) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 7,117 units (SEC Form 4)